Merck KGaA (OTCMKTS:MKGAF) Upgraded at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Merck KGaA (OTCMKTS:MKGAF) from a sell rating to a hold rating in a report issued on Tuesday morning, ValuEngine reports.

Shares of MKGAF stock opened at $114.58 on Tuesday. Merck KGaA has a 12-month low of $96.00 and a 12-month high of $121.40. The business’s fifty day simple moving average is $117.81 and its 200-day simple moving average is $109.00. The company has a current ratio of 0.94, a quick ratio of 0.68 and a debt-to-equity ratio of 0.29. The company has a market cap of $14.82 billion, a PE ratio of 20.44 and a beta of 0.69.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Marijuana Stocks Future Looks Bright

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.